Telegraft

Official Newsletter of ISCT

[Joaquim Vives @xinoxan]

🌍 #FORUM30 united 102 experts from 36 countries to advance MPHO safety&traceability! Hosted by @ICCBBA, @CNTrapianti, @CentroSangue & supported by @WHO, we explored future therapies & global regulatory harmony. A pivotal step for patient care worldwide!
🔗https://t.co/9dEFPf4hTD

[Joaquim Vives @xinoxan]

📢now #online in the latest isse of @ISCTglobal @telegraft a recap of @ISBT128's a brief recap of #FORUM30 where I presented Current challenges in cell and gene therapy: a joint view from the European Committee of the @ISCTglobal and the @TheEBMT
🔗https://t.co/t70b5Pvd7T

[Joaquim Vives @xinoxan]

📢Now online! Human pluripotent stem cell-derived #retinal #pigment #epithelial cells #underthemicroscope by Dr. Laura Baqué Vidal @karolinskainst in the latest issue of @telegraft, the newsletter of the @ISCTglobal
🔗https://t.co/AjAZijm69H

[Joaquim Vives @xinoxan]

Advances in stem-cell #therapy could hold the key to treating age-related #macular degeneration (AMD), a leading cause of blindness. Learn how retinal pigment epithelial (RPE) cells are being developed to stop #vision loss & offer new hope for millions worldwide! #AMD @telegraft

[Joaquim Vives @xinoxan]

@telegraft 🤔What?🧐RPE are specialized cells on the back of the eye playing a fundamental role in the homeostasis of the #retina, e.g. visual cycle recycling, phagocytosis of old photoreceptors, secretion of growth factors, transport of nutrients and water, capture of not-transduced light

[Joaquim Vives @xinoxan]

@telegraft @ISCTglobal 🤔Why?🧐Age-related #macular #degeneration (AMD) is a prevalent progressive #blindness disease in the elderly worldwide caused by degeneration of #RPEs. Cell replacement therapies could help in the #treatment of AMD.
📚https://t.co/wbb057mhpW

[Joaquim Vives @xinoxan]

@telegraft @ISCTglobal 🤔Who?🧐Current strategies for treating AMD involve stem-cell-based RPE products develop in both academua and industry.
🔗https://t.co/gGHN3fbfUe

[Joaquim Vives @xinoxan]

@telegraft @ISCTglobal 🤔When?🧐The interest on transplanting #RPE into #AMD patients started in the early 90's, when #fetal tissue material was used to transplant young and healthy RPEs that were able to slightly rescue some visual acuity in patients.
🔗https://t.co/53lNdIkAmM

[Joaquim Vives @xinoxan]

@telegraft @ISCTglobal 🤔Where?🧐Leading countries developing clinical development of stem-cell-based RPE products include USA, Japan, Israel, UK, China and Republic of Korea. In some other countries, developments are still on the preclinical stage, including Sweden, Spain, India, Finland, Singapore.

[Joaquim Vives @xinoxan]

@telegraft @ISCTglobal 🤔How?🧐#Stem cell-based #RPE products are #ATMP produced in compliance with pharmaceutical #GMP standards. Current #protocols yield >98% pure RPEs, although some developers use cell sorting procedures to enrich #RPEs from other #impurities.

[Joaquim Vives @xinoxan]

@telegraft @ISCTglobal 🤔Did you know that…🧐#RPE have granules of #melanin, the same substance found in the skin that protects us from #UVlight and responsible of the color of our #hair? This makes it easier to work with these cells because they can be easily spotted for their dark brown color.

[Joaquim Vives @xinoxan]

@telegraft @ISCTglobal 💡If you want to learn more on #pluripotent #stem cell-derived #epithelial #retinal #pigmental #cells, please read Dr. Laura Baqué Vidal's article in the latest issue of @Telegraft following this link:
https://t.co/AjAZijmDZf

[Joaquim Vives @xinoxan]

In this #UTM @telegraft article, @CaicedoLab & @sebastianjpc1 present #mitochondria as a cell-free therapeutic option.
🔗https://t.co/6KD2zQOGGh

[Joaquim Vives @xinoxan]

@telegraft @CaicedoLab @sebastianjpc1 @ISCTglobal 🤔Why?🧐The simplicity of AMT/T contrasts with complexity of studying its potential #therapeutic effect based on the principle that damaged cells and tissues require #mitochondria to support phenotypic recovery via nanotubular structures and microvesicles.
https://t.co/f5oaMJvQId

[Joaquim Vives @xinoxan]

@telegraft @CaicedoLab @sebastianjpc1 @ISCTglobal 🤔What? 🧐#Mitochondria enabled #evolution& #diversification of complex life forms, driving energy production and support cellular #signaling, #survival& #cellularcommunication, leading to development of artificial mitochondrial transfer/transplant (AMT/T)
https://t.co/Q9SlxTx6gi

[Joaquim Vives @xinoxan]

📢 #mitochondria as a #therapeutic option this month in the latest issue of @ISCTglobal @telegraft by Drs. Caicedo lab from @USFQ_Ecuador
🔗 https://t.co/6KD2zQOGGh

[Joaquim Vives @xinoxan]

@telegraft @CaicedoLab @sebastianjpc1 @ISCTglobal 🤔How?🧐#Challenges exist in the GMP #scaleup #manufacturing of mitochondria from healthy tissues in accordance to #pharmaceutical #regulations. Advances in production of other AdvancedTherapies might help in the sourcing of viable & functonal mitochondria
https://t.co/sCbilKlXnu

[Joaquim Vives @xinoxan]

@telegraft @CaicedoLab @sebastianjpc1 @ISCTglobal 🤔Who?🧐There's no #commercial mitochondria preparations as #LivingDrug yet. However, the evidence that cells uptake #mitochondria from their surroundings or from other cells has spurred #interest in both in #academia and #industry.
https://t.co/o2teauT1T3

[Dr. Ashley Krull, Ph.D. @AshleyAKrull]

I am thrilled to have my video interview for the @ISCTglobal @telegraft Member Spotlight with Dr. Erja Kerkelä, Ph.D. out now! Enjoy this wonderful conversation with a fantastic researcher and champion of team science! https://t.co/mJgV1IzAHa via @YouTube

[Dr. Ashley Krull, Ph.D. @AshleyAKrull]

My latest editorial on CAR-MSCs for the @ISCTglobal @telegraft - had a lot of fun writing this one! Check out the inspiration article from @kenderian_ss linked within. Enjoy! #celltherapy